Researchers who used the company's service presented data this week from analyses of sarcoma patients that they believe can help personalize care.
BMS amended an ongoing Phase III study of Opdivo and Yervoy to evaluate outcomes based on tumor mutational burden using Foundation Medicine's NGS companion diagnostic.
A Memorial Sloan Kettering Cancer Center-led team has followed more than 50 patients for more than two years after receiving immunotherapy, Time reports.
Stand Up to Cancer is teaming with Microsoft and SITC to provide a new round of $11 million in grants to study cancer immunotherapies.
The company is aiming to make its Digital Spatial Profiling technology compatible with NGS and will present customer data from its Hyb & Seq at AGBT.
Over the next three years, the company and its partners will assess the OneRNA platform to diagnose bladder cancer, select treatment, and measure response and recurrence.
In Science this week: genetics of cancer susceptibility to immune checkpoint inhibition, and more.
Teams studying kidney and skin cancers independently implicated SWI/SNF chromatin remodeling mutations in checkpoint blockade immunotherapy response.
Researchers genotyped advanced cancer patients treated with immunotherapies and found that homozygosity at HLA loci was linked to decreased survival.
The partners will use the GuardantOMNI assay, a 500-plus-gene liquid biopsy panel designed to accelerate clinical trials and targeted cancer therapy research.
Holden Thorp is to be the new editor-in-chief of Science and its related journals.
A genetic analysis of salmon scales collected over the course of a century points to a sharp decline in the number of fish returning each year to river in British Columbia, CBC reports.
Adelaide University has suspended the head of an ancient DNA lab as its investigation of workplace bullying continues, Australia's ABC News reports.
In PNAS this week: gene expression profiles of adipocyte subtypes, computational approach for improving plant expressome analysis, and more.